Yi Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yi Liu has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Jing Wang
Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
3 shared publicationsXin Ye
Department of Thoracic Surgery, Beijing Chaoyang Hospital, Beijing 100020, China
3 shared publications- Bin Hu
Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China
2 shared publications Qirui Chen
Department of Thoracic Surgery, Beijing Chaoyang Hospital, Beijing 100020, China
2 shared publicationsYan Zhao
Department of Thoracic Surgery, Beijing Chaoyang Hospital, Beijing 100020, China
2 shared publicationsYanhua Tang
Department of Radiology, Beijing Chaoyang Hospital, Beijing, China
2 shared publications
Latest Publications
- Open Access
Association Between Neutrophil Percentage-to-Albumin Ratio (NPAR) and the Prognosis of Non-Small-Cell Lung Cancer
Objective: This study investigates the prognostic value and clinical utility of the neutrophil percentage-to-albumin ratio (NPAR) in patients with resected non-small-cell lung cancer (NSCLC). Methods: We retrospectively included 335 patients with NSCLC who underwent lung resection at our institution between January 2017 and October 2018. Optimal cutoffs for preoperative and postoperative day 1 (D1) NPAR were determined using X-tile (version 3.6.1; Yale University, New Haven, CT, USA) to define high and low groups. Overall survival (OS) was evaluated using Kaplan–Meier analysis and Cox proportional hazards models. A perioperative NPAR trajectory (low–low, low–high, high–low, high–high) was constructed to characterize dynamic risk patterns. To mitigate potential bias associated with postoperative measurements, a D1 landmark analysis was performed. A nomogram was developed based on the multivariable model and assessed by calibration at 1, 3, and 5 years. Incremental clinical value beyond TNM stage and surgical approach was evaluated using decision curve analysis (DCA), as well as by 5-year continuous net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Results: The optimal cutoffs for preoperative and postoperative D1 NPAR were 14.5 and 23.1, respectively. In univariate analyses, sex, smoking history, preoperative NPAR, postoperative D1 NPAR, pathologic type, TNM stage, surgical approach, and adjuvant therapy were associated with OS (all p < 0.01). In multivariable Cox regression, high preoperative NPAR (HR 1.896, 95% CI 1.135–3.168; p = 0.014) and high postoperative D1 NPAR (HR 1.905, 95% CI 1.097–3.305; p = 0.014) were independent risk factors, along with TNM stage (Stage II: HR 2.824, 95% CI 1.209–6.595; p = 0.016; Stage III: HR 9.470, 95% CI 4.935–18.171; p < 0.001) and open surgery (HR 2.350, 95% CI 1.341–4.117; p = 0.003). Trajectory analysis further stratified risk, with the high–high group showing the poorest survival (adjusted HR 3.48, 95% CI 1.43–8.47; p = 0.006). The association of postoperative NPAR persisted in the D1 landmark analysis (HR 1.836, 95% CI 1.071–3.148; p = 0.027). Adding NPAR to TNM stage and surgical approach improved 5-year risk reclassification (continuous NRI 0.377, 95% CI 0.094–0.659; IDI 0.028, 95% CI −0.002–0.054) and increased net benefit on DCA. The nomogram demonstrated acceptable calibration at 1, 3, and 5 years. Conclusions: This study demonstrates that NPAR serves as an independent prognostic marker for long-term outcomes in patients with NSCLC. The use of NPAR offers clinicians a comprehensive and precise tool for assessing patient prognosis.
Open AccessAssociation Between Neutrophil Percentage-to-Albumin Ratio (NPAR) and the Prognosis of Non-Small-Cell Lung Cancer
Objective: This study investigates the prognostic value and clinical utility of the neutrophil percentage-to-albumin ratio (NPAR) in patients with resected non-small-cell lung cancer (NSCLC). Methods: We retrospectively included 335 patients with NSCLC who underwent lung resection at our institution between January 2017 and October 2018. Optimal cutoffs for preoperative and postoperative day 1 (D1) NPAR were determined using X-tile (version 3.6.1; Yale University, New Haven, CT, USA) to define high and low groups. Overall survival (OS) was evaluated using Kaplan–Meier analysis and Cox proportional hazards models. A perioperative NPAR trajectory (low–low, low–high, high–low, high–high) was constructed to characterize dynamic risk patterns. To mitigate potential bias associated with postoperative measurements, a D1 landmark analysis was performed. A nomogram was developed based on the multivariable model and assessed by calibration at 1, 3, and 5 years. Incremental clinical value beyond TNM stage and surgical approach was evaluated using decision curve analysis (DCA), as well as by 5-year continuous net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Results: The optimal cutoffs for preoperative and postoperative D1 NPAR were 14.5 and 23.1, respectively. In univariate analyses, sex, smoking history, preoperative NPAR, postoperative D1 NPAR, pathologic type, TNM stage, surgical approach, and adjuvant therapy were associated with OS (all p < 0.01). In multivariable Cox regression, high preoperative NPAR (HR 1.896, 95% CI 1.135–3.168; p = 0.014) and high postoperative D1 NPAR (HR 1.905, 95% CI 1.097–3.305; p = 0.014) were independent risk factors, along with TNM stage (Stage II: HR 2.824, 95% CI 1.209–6.595; p = 0.016; Stage III: HR 9.470, 95% CI 4.935–18.171; p < 0.001) and open surgery (HR 2.350, 95% CI 1.341–4.117; p = 0.003). Trajectory analysis further stratified risk, with the high–high group showing the poorest survival (adjusted HR 3.48, 95% CI 1.43–8.47; p = 0.006). The association of postoperative NPAR persisted in the D1 landmark analysis (HR 1.836, 95% CI 1.071–3.148; p = 0.027). Adding NPAR to TNM stage and surgical approach improved 5-year risk reclassification (continuous NRI 0.377, 95% CI 0.094–0.659; IDI 0.028, 95% CI −0.002–0.054) and increased net benefit on DCA. The nomogram demonstrated acceptable calibration at 1, 3, and 5 years. Conclusions: This study demonstrates that NPAR serves as an independent prognostic marker for long-term outcomes in patients with NSCLC. The use of NPAR offers clinicians a comprehensive and precise tool for assessing patient prognosis.
- Open Access
- 1 June 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (6) , 3886-3896
The value of prognostic immune-inflammatory-nutritional score in predicting survival after surgery in stage I–III non-small cell lung cancer
Background: Non-small cell lung cancer (NSCLC) remains one of the leading causes of cancer-related mortality worldwide. While traditional prognostic factors have mainly focused on tumor characteristics, recent evidence underscores the importance of immune response, inflammation, and nutritional status in determining patient outcomes. This study assesses the prognostic value of prognostic immune-inflammatory-nutritional (PIIN) score in predicting overall survival (OS) of NSCLC patients. Methods: A retrospective analysis was conducted on the clinical data of 406 NSCLC patients who underwent surgical treatment. The optimal PIIN score cut-off value was established using receiver operating characteristic (ROC) curve analysis, dividing patients into high and low PIIN score groups. Both univariate and multivariate Cox regression analyses identified independent prognostic factors, which were used to construct a nomogram. Results: The ideal PIIN score cut-off value was 24.2. Multivariate Cox regression analysis demonstrated that PIIN score [hazard ratio (HR): 2.116, 95% confidence interval (CI): 1.305–3.430, P=0.002], tumor-node-metastasis (TNM) stage (stage II: HR: 2.437, 95% CI: 1.223–4.855, P=0.01; stage III: HR: 6.753, 95% CI: 3.779–12.065, P1) (HR: 2.335, 95% CI: 1.402–3.889, P=0.001) were independent prognostic factors. The concordance index (C-index) of the nomogram constructed based on independent risk factors was 0.838 (95% CI: 0.736–0.906). ROC analysis showed that the area under the curve (AUC) values for the nomogram’s prediction of 1-, 3-, and 5-year OS were 0.843, 0.831, and 0.825, respectively. Conclusions: PIIN score was validated as an independent and reliable predictor of OS in stage I–III NSCLC patients after surgery. This score provides a valuable tool for individualized prognosis evaluation in clinical practice.
- 1 June 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (6) , 3886-3896
Open AccessThe value of prognostic immune-inflammatory-nutritional score in predicting survival after surgery in stage I–III non-small cell lung cancer
Background: Non-small cell lung cancer (NSCLC) remains one of the leading causes of cancer-related mortality worldwide. While traditional prognostic factors have mainly focused on tumor characteristics, recent evidence underscores the importance of immune response, inflammation, and nutritional status in determining patient outcomes. This study assesses the prognostic value of prognostic immune-inflammatory-nutritional (PIIN) score in predicting overall survival (OS) of NSCLC patients. Methods: A retrospective analysis was conducted on the clinical data of 406 NSCLC patients who underwent surgical treatment. The optimal PIIN score cut-off value was established using receiver operating characteristic (ROC) curve analysis, dividing patients into high and low PIIN score groups. Both univariate and multivariate Cox regression analyses identified independent prognostic factors, which were used to construct a nomogram. Results: The ideal PIIN score cut-off value was 24.2. Multivariate Cox regression analysis demonstrated that PIIN score [hazard ratio (HR): 2.116, 95% confidence interval (CI): 1.305–3.430, P=0.002], tumor-node-metastasis (TNM) stage (stage II: HR: 2.437, 95% CI: 1.223–4.855, P=0.01; stage III: HR: 6.753, 95% CI: 3.779–12.065, P1) (HR: 2.335, 95% CI: 1.402–3.889, P=0.001) were independent prognostic factors. The concordance index (C-index) of the nomogram constructed based on independent risk factors was 0.838 (95% CI: 0.736–0.906). ROC analysis showed that the area under the curve (AUC) values for the nomogram’s prediction of 1-, 3-, and 5-year OS were 0.843, 0.831, and 0.825, respectively. Conclusions: PIIN score was validated as an independent and reliable predictor of OS in stage I–III NSCLC patients after surgery. This score provides a valuable tool for individualized prognosis evaluation in clinical practice.
- 8 April 2025
- Published by Royal Society of Chemistry (RSC) in CrystEngComm
- Vol. 27 (19) , 2979-2992
Diving into the invisible region—a review of crystallographic-site-dependent ultraviolet and near-infrared luminescence of the garnet structure
Invisible luminescence materials have attracted considerable attention due to their versatile applications in sterilization, photocatalysis, plant growth, night vision, and laser technology.
- 8 April 2025
- Published by Royal Society of Chemistry (RSC) in CrystEngComm
- Vol. 27 (19) , 2979-2992
Diving into the invisible region—a review of crystallographic-site-dependent ultraviolet and near-infrared luminescence of the garnet structure
Invisible luminescence materials have attracted considerable attention due to their versatile applications in sterilization, photocatalysis, plant growth, night vision, and laser technology.
- Open Access
- 1 December 2023
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 12 (12) , 2494-2504
Deep learning-assisted development and validation of an algorithm for predicting the growth of persistent pure ground-glass nodules
Background: The prediction of the persistent pure ground-glass nodule (pGGN) growth is challenging and limited by subjective assessment and variation across radiologists. A chest computed tomography (CT) image-based deep learning classification model (DLCM) may provide a more accurate growth prediction. Methods: This retrospective study enrolled consecutive patients with pGGNs from January 2010 to December 2020 from two independent medical institutions. Four DLCM algorithms were built to predict the growth of pGGNs, which were extracted from the nodule areas of chest CT images annotated by two radiologists. All nodules were assigned to either the study, the inner validation, or the external validation cohort. Accuracy, sensitivity, specificity, receiver operating characteristic (ROC) curves, and areas under the ROC curve (AUROCs) were analyzed to evaluate our models. Results: A total of 286 patients were included, with 419 pGGN. In total, 197 (68.9%) of the patients were female and the average age was 59.5±12.0 years. The number of pGGN assigned to the study, the inner validation, and the external validation cohort were 193, 130, and 96, respectively. The follow-up time of stable pGGNs for the primary and external validation cohorts were 3.66 (range, 2.01–10.08) and 4.63 (range, 2.00–9.91) years, respectively. Growth of the pGGN occurred in 166 nodules [83 (43%), 39 (30%), and 44 (45%) in the study, inner and external validation cohorts respectively]. The best-performing DLCM algorithm was DenseNet_DR, which achieved AUROCs of 0.79 [95% confidence interval (CI): 0.70, 0.86] in predicting pGGN growth in the inner validation cohort and 0.70 (95% CI: 0.60, 0.79) in the external validation cohort. Conclusions: DLCM algorithms that use chest CT images can help predict the growth of pGGNs.
- 1 December 2023
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 12 (12) , 2494-2504
Open AccessDeep learning-assisted development and validation of an algorithm for predicting the growth of persistent pure ground-glass nodules
Background: The prediction of the persistent pure ground-glass nodule (pGGN) growth is challenging and limited by subjective assessment and variation across radiologists. A chest computed tomography (CT) image-based deep learning classification model (DLCM) may provide a more accurate growth prediction. Methods: This retrospective study enrolled consecutive patients with pGGNs from January 2010 to December 2020 from two independent medical institutions. Four DLCM algorithms were built to predict the growth of pGGNs, which were extracted from the nodule areas of chest CT images annotated by two radiologists. All nodules were assigned to either the study, the inner validation, or the external validation cohort. Accuracy, sensitivity, specificity, receiver operating characteristic (ROC) curves, and areas under the ROC curve (AUROCs) were analyzed to evaluate our models. Results: A total of 286 patients were included, with 419 pGGN. In total, 197 (68.9%) of the patients were female and the average age was 59.5±12.0 years. The number of pGGN assigned to the study, the inner validation, and the external validation cohort were 193, 130, and 96, respectively. The follow-up time of stable pGGNs for the primary and external validation cohorts were 3.66 (range, 2.01–10.08) and 4.63 (range, 2.00–9.91) years, respectively. Growth of the pGGN occurred in 166 nodules [83 (43%), 39 (30%), and 44 (45%) in the study, inner and external validation cohorts respectively]. The best-performing DLCM algorithm was DenseNet_DR, which achieved AUROCs of 0.79 [95% confidence interval (CI): 0.70, 0.86] in predicting pGGN growth in the inner validation cohort and 0.70 (95% CI: 0.60, 0.79) in the external validation cohort. Conclusions: DLCM algorithms that use chest CT images can help predict the growth of pGGNs.
- Open Access
- 25 March 2023
- Published by Impact Journals, LLC in Aging
- Vol. 15 (6) , 2293-2307
Construction and validation of a hypoxia-related risk signature identified EXO1 as a prognostic biomarker based on 12 genes in lung adenocarcinoma
Background: Increasing evidence has demonstrated the clinical importance of hypoxia and its related factors in lung adenocarcinoma (LUAD). Methods: RNA-seq datasets from The Cancer Genome Atlas (TCGA) were analyzed using the differentially expressed genes in hypoxia pathway by the Least Absolute Shrinkage and Selection Operator (LASSO) model. Applying gene ontology (GO) and gene set enrichment analysis (GSEA), a risk signature associated with the survival of LUAD patients was constructed between LUAD and normal tissue. Results: In total, 166 hypoxia-related genes were identified. Based on the LASSO Cox regression, 12 genes were selected for the development of the risk signature. Then, we designed an OS-associated nomogram that included the risk score and clinical factors. The concordance index of the nomogram was 0.724. ROC curve showed better predictive ability using the nomogram (AUC = 0.811 for 5-year OS). Finally, the expressions of the 12 genes were validated in two external datasets and EXO1 was recognized as a potential biomarker in the progression of LUAD patients. Conclusions: Overall, our data suggested that hypoxia is associated with the prognosis, and EXO1 acted as a promising biomarker in LUAD.
- 25 March 2023
- Published by Impact Journals, LLC in Aging
- Vol. 15 (6) , 2293-2307
Open AccessConstruction and validation of a hypoxia-related risk signature identified EXO1 as a prognostic biomarker based on 12 genes in lung adenocarcinoma
Background: Increasing evidence has demonstrated the clinical importance of hypoxia and its related factors in lung adenocarcinoma (LUAD). Methods: RNA-seq datasets from The Cancer Genome Atlas (TCGA) were analyzed using the differentially expressed genes in hypoxia pathway by the Least Absolute Shrinkage and Selection Operator (LASSO) model. Applying gene ontology (GO) and gene set enrichment analysis (GSEA), a risk signature associated with the survival of LUAD patients was constructed between LUAD and normal tissue. Results: In total, 166 hypoxia-related genes were identified. Based on the LASSO Cox regression, 12 genes were selected for the development of the risk signature. Then, we designed an OS-associated nomogram that included the risk score and clinical factors. The concordance index of the nomogram was 0.724. ROC curve showed better predictive ability using the nomogram (AUC = 0.811 for 5-year OS). Finally, the expressions of the 12 genes were validated in two external datasets and EXO1 was recognized as a potential biomarker in the progression of LUAD patients. Conclusions: Overall, our data suggested that hypoxia is associated with the prognosis, and EXO1 acted as a promising biomarker in LUAD.
- Open Access
- 1 February 2023
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 15 (2) , 620-626
Risk factor analysis of postoperative cerebral infarction in thoracic surgery patients by propensity-score matching-a single institution retrospective cohort study
Background: Postoperative cerebral infarction (PCI) is serious complication for thoracic surgery patients, however, the risk factors still unclear. This study sought to investigate the incidence risk factors of postoperative cerebral infarction after thoracic surgery. Methods: Patients who underwent thoracic surgery from 2011 to 2022 at Beijing Chaoyang Hospital were identified and followed-up for 30 days postoperatively to determine the primary outcome of PCI. Patients with PCI were identified as the PCI cohort, and those without PCI were identified as the non-PCI cohort. The clinical data of all the patients were collected. The Mann-Whitney U test and chi-square test were used to analyze the baseline differences. Propensity-score matching (PSM) at a ratio of 1:4 was used to match the variables between the 2 cohorts, and a stepwise univariate conditional logistic regression was used to analyze the risk factors of PCI. Results: We enrolled 8,448 consecutive patients who underwent thoracic surgeries, including 21 with PCI and 8,827 without PCI. Among the 21 PCI patients, 6 patients died. A history of cerebral infarction [odds ratio (OR) = 4.38, P=0.037], perioperative blood transfusion (OR =6.22, P=0.013), a history of deep vein thrombosis (DVT) (OR =5.25, P=0.022), and hyperlipidemia (OR =13.76, PConclusions: PCI patients who undergo thoracic surgery have a poor prognosis. A history of cerebral infarction, perioperative blood transfusion, a history of DVT, and hyperlipidemia are risk factors of PCI. Patients with risk factors may need prevention measure and assist clinician for early diagnosis of PCI.
- 1 February 2023
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 15 (2) , 620-626
Open AccessRisk factor analysis of postoperative cerebral infarction in thoracic surgery patients by propensity-score matching-a single institution retrospective cohort study
Background: Postoperative cerebral infarction (PCI) is serious complication for thoracic surgery patients, however, the risk factors still unclear. This study sought to investigate the incidence risk factors of postoperative cerebral infarction after thoracic surgery. Methods: Patients who underwent thoracic surgery from 2011 to 2022 at Beijing Chaoyang Hospital were identified and followed-up for 30 days postoperatively to determine the primary outcome of PCI. Patients with PCI were identified as the PCI cohort, and those without PCI were identified as the non-PCI cohort. The clinical data of all the patients were collected. The Mann-Whitney U test and chi-square test were used to analyze the baseline differences. Propensity-score matching (PSM) at a ratio of 1:4 was used to match the variables between the 2 cohorts, and a stepwise univariate conditional logistic regression was used to analyze the risk factors of PCI. Results: We enrolled 8,448 consecutive patients who underwent thoracic surgeries, including 21 with PCI and 8,827 without PCI. Among the 21 PCI patients, 6 patients died. A history of cerebral infarction [odds ratio (OR) = 4.38, P=0.037], perioperative blood transfusion (OR =6.22, P=0.013), a history of deep vein thrombosis (DVT) (OR =5.25, P=0.022), and hyperlipidemia (OR =13.76, PConclusions: PCI patients who undergo thoracic surgery have a poor prognosis. A history of cerebral infarction, perioperative blood transfusion, a history of DVT, and hyperlipidemia are risk factors of PCI. Patients with risk factors may need prevention measure and assist clinician for early diagnosis of PCI.
- Open Access
- 24 June 2021
- Published by Wiley in Thoracic Cancer
- Vol. 12 (15) , 2189-2197
Development and validation of tumor‐to‐blood based nomograms for preoperative prediction of lymph node metastasis in lung cancer
Background: To develop and validate tumor‐to‐blood based nomograms for preoperative prediction of lymph node (LN) metastasis in patients with lung cancer (LC).Methods: A prediction model was developed in a primary cohort comprising 330 LN stations from patients with pathologically confirmed LC, these data having been gathered from January 2016 to June 2019. Tumor‐to‐blood variables of LNs were calculated from positron emission tomography‐computed tomography (PET‐CT) images of LC and the short axis diameters of LNs were measured on CT images. Tumor‐to‐blood variables, number of stations suspected of harboring LN metastasis according to PET, and independent clinicopathological risk factors were included in the final nomograms. After being internally validated, the nomograms were used to assess an independent validation cohort containing 101 consecutive LN stations accumulated from July 2019 to March 2020.Results: Four tumor‐to‐blood variables (left atrium, inferior vena cava, liver, and aortic arch) and the maximum standardized uptake value (SUVmax) for LNs were found to be significantly associated with LN status (p < 0.001 for both primary and validation cohorts). Five predictive nomograms were built. Of these, one with LN SUVmax/left atrium SUVmax was found to be optimal for predicting LN status with AUC 0.830 (95% confidence interval [CI]: 0.774–0.886) in the primary cohort and AUC 0.865 (95% CI: 0.782–0.948) in the validation cohort. All models showed good discrimination, with a modest C‐index, and good calibration in both primary and validation cohorts.Conclusions: We have developed tumor‐to‐blood based nomograms that incorporate identified clinicopathological risk factors and facilitate preoperative prediction of LN metastasis in LC patients.
- 24 June 2021
- Published by Wiley in Thoracic Cancer
- Vol. 12 (15) , 2189-2197
Open AccessDevelopment and validation of tumor‐to‐blood based nomograms for preoperative prediction of lymph node metastasis in lung cancer
Background: To develop and validate tumor‐to‐blood based nomograms for preoperative prediction of lymph node (LN) metastasis in patients with lung cancer (LC).Methods: A prediction model was developed in a primary cohort comprising 330 LN stations from patients with pathologically confirmed LC, these data having been gathered from January 2016 to June 2019. Tumor‐to‐blood variables of LNs were calculated from positron emission tomography‐computed tomography (PET‐CT) images of LC and the short axis diameters of LNs were measured on CT images. Tumor‐to‐blood variables, number of stations suspected of harboring LN metastasis according to PET, and independent clinicopathological risk factors were included in the final nomograms. After being internally validated, the nomograms were used to assess an independent validation cohort containing 101 consecutive LN stations accumulated from July 2019 to March 2020.Results: Four tumor‐to‐blood variables (left atrium, inferior vena cava, liver, and aortic arch) and the maximum standardized uptake value (SUVmax) for LNs were found to be significantly associated with LN status (p < 0.001 for both primary and validation cohorts). Five predictive nomograms were built. Of these, one with LN SUVmax/left atrium SUVmax was found to be optimal for predicting LN status with AUC 0.830 (95% confidence interval [CI]: 0.774–0.886) in the primary cohort and AUC 0.865 (95% CI: 0.782–0.948) in the validation cohort. All models showed good discrimination, with a modest C‐index, and good calibration in both primary and validation cohorts.Conclusions: We have developed tumor‐to‐blood based nomograms that incorporate identified clinicopathological risk factors and facilitate preoperative prediction of LN metastasis in LC patients.